Nasdaq News

Key PointsNvidia expects to grow at a strong pace again in 2027.

(RTTNews) - The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.

Key PointsTwenty-four of 32 analysts covering Intuitive Surgical rate the stock as a "buy" or "strong buy."

(RTTNews) - PZ Cussons plc (PZC.L), a consumer goods company, on Thursday reported 4.5 percent like-for-like revenue growth in the first quarter of fiscal 2027.

Key PointsThree hundred monthly purchases of $500 each, starting in October 2001, totaled $150,000 in contributions.

(RTTNews) - Pliant Therapeutics (PLRX), a clinical-stage biotechnology company focused on developing integrin-based therapeutics, announced the appointment of David Raben, M.D., as Chief Medical Officer.

(RTTNews) - CVS Health (CVS), a health solutions company, announced that its board of directors approved a quarterly dividend of $0.665 per share of the corporation's common stock. The dividend is payable on November 2, 2026, to holders of record on October 22, 2026.

(RTTNews) - Pfizer Inc. (PFE) presented detailed Phase 2 results showing that tilrekimig achieved significant improvements in skin clearance in adults with moderate-to-severe atopic dermatitis, supporting continued development of the investigational therapy.

Key PointsCameco co-owns Westinghouse, which could have a massive IPO relatively soon.

Key PointsIn more than a decade of trading, the XRP token has never traded higher than a price of $3.84.

Key PointsSeveral notable stock market crashes have occurred in October.

Key PointsFed Chair Kevin Warsh and the Federal Open Market Committee (FOMC) commenced a rate-hiking cycle for only the fourth time this century.

(RTTNews) - ADS-TEC Energy PLC (ADSE), a German battery storage and ultra-fast charging solutions provider, on Thursday reported a wider net loss in the first half of fiscal 2026, while operating loss narrowed on expense control, amid weak revenues.

Key PointsNvidia’s stock is up 22% this year, while its forward price-to-earnings ratio has dropped 38%.

Key PointsOctober is when the Social Security Administration typically announces key changes to the program.

(RTTNews) - Zealand Pharma A/S (ZEAL.CO) said Thursday that Boehringer Ingelheim's investigational Survodutide met its co-primary endpoints in the Phase 3 SYNCHRONIZE-2 trial in adults with obesity or overweight and type 2 diabetes.

(RTTNews) - Kia Corporation (000270.KS), a South Korean automobiles manufacturer, Thursday said that its American subsidiary, reported higher September vehicle sales compared to the same period last year.

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that detailed Phase 3 evERA study results published in the New England Journal of Medicine showed that giredestrant combined with everolimus significantly improved progression-free survival in patients with ER-

Key PointsMichael Burry replaced his Micron short position with put options that expire in June 2027.

(RTTNews) - H. Lundbeck A/S (HLBBF), a biopharmaceutical company, announced positive results from the Phase IV THRIVE trial evaluating eptinezumab in adults with migraine who had an inadequate response to one prior calcitonin gene-related peptide (CGRP)-targeting preventive thera